NCT04502472

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2)

• Status: Terminated
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 109 (actual)
• Sponsor: Inova Health Care Services · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The investigators hypothesize that use of convalescent plasma donated from individuals recovered from Coronavirus Disease 2019 (COVID-19) will help expedite recovery of individuals with active, severe COVID-19 infection.

Detailed description

The purpose of this research study is to see if convalescent plasma is safe and effective for the treatment of patients acutely ill with COVID-19. The researchers want to confirm the right dose levels of immunoglobulins/antibodies (immune proteins) and find out what therapeutic effects plasma donated by recovered individuals has on people severely sick with COVID-19.

Conditions

• Covid-19

Interventions

Type	Name	Description
BIOLOGICAL	Convalescent plasma transfusion	Transfusion of COVID-19 convalescent plasma to participants currently hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome.

Timeline

• Start date: 2020-06-06
• Primary completion: 2020-09-30
• Completion: 2020-09-30
• First posted: 2020-08-06
• Last updated: 2022-01-10
• Results posted: 2022-01-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study